ALKS
Alkermes plc
ALKS lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
ALKS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Stable | |
| Weak |
ALKS's revenue is currently healthy, and its cash flow is stable, but its profitability and balance sheet are under pressure.
ALKS PE Valuation
ALKS has no meaningful PE right now: it lost money over the past year.
ALKS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect ALKS's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
ALKS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.02 | -101% |
| Q2 2026 | $0.38 | -82% |
| Q1 2026 | $0.90 | -57% |
| Q4 2025 | $1.43 | -34% |
| Q3 2025 | $2.02 | +2% |
| Q2 2025 | $2.08 | +22% |
| Q1 2025 | $2.09 | -18% |
| Q4 2024 | $2.17 | +3.3% |
ALKS has swung to a loss: it lost $0.02 per share over the past year, after a profit the year before.
ALKS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $480.1M | +22% |
| Q2 2026 | $496M | +27% |
| Q1 2026 | $392.9M | +28% |
| Q4 2025 | $384.5M | -11% |
| Q3 2025 | $394.2M | +4.2% |
| Q2 2025 | $390.7M | -2.1% |
| Q1 2025 | $306.5M | -13% |
| Q4 2024 | $430M | +14% |
ALKS's revenue is recovering but still below its 2023 peak: $480M last quarter, up 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.5% | -15 points |
| Q2 2026 | 3.7% | -20 points |
| Q1 2026 | -12% | -17 points |
| Q4 2025 | 15% | -23 points |
| Q3 2025 | 23% | -5.1 points |
| Q2 2025 | 24% | -3.7 points |
| Q1 2025 | 4.5% | -7.9 points |
| Q4 2024 | 38% | -9.5 points |
ALKS's operating margin was 7.5% last quarter, down 15 points from the same quarter a year ago.
ALKS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $90.1M | +6.8% |
| Q2 2026 | $137M | -0.1% |
| Q1 2026 | -$169.8M | -291% |
| Q4 2025 | $170.1M | -5.8% |
| Q3 2025 | $84.4M | +15% |
| Q2 2025 | $137.2M | -1.2% |
| Q1 2025 | $88.7M | +595% |
| Q4 2024 | $180.6M | +100% |
ALKS still generates free cash flow, though less than at its 2023 peak: $227M over the past year.
ALKS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.0x | High |
| Q2 2026 | 5.5x | High |
| Q1 2026 | 5.0x | High |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -1.3x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q3 2024 | -0.2x | Net Cash |
ALKS's net debt is about 6.0 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
ALKS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.9 | Neutral |
| Stochastic | 53.5 | Neutral |
ALKS's weekly RSI is 59 (neutral) and its Stochastic is 53 (neutral).
ALKS PE vs Healthcare Sector
| Metric | ALKS | Sector median | Relative |
|---|---|---|---|
| PE | 119x | 26x | 362% above |
| PE % | 96 | 29 | 67 pts above |
ALKS has no meaningful PE right now: it lost money over the past year.
ALKS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.3 | 8.5% above |
| 20 week MA | $46.8 | 0.3% above |
| 50 week MA | $39.2 | 20% above |
| 100 week MA | $34.7 | 35% above |
| 200 week MA | $31.2 | 51% above |
ALKS is in an uptrend: it's above all five of its weekly moving averages, and 51% above its 200-week average.
ALKS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $20.4 | $21.5 | +5% |
| 2021 | $21.5 | $24.1 | +12% |
| 2022 | $24.1 | $25.5 | +5.8% |
| 2023 | $25.5 | $27.7 | +8.8% |
| 2024 | $27.7 | $29.6 | +6.5% |
| 2025 | $29.6 | $28.5 | -3.6% |
| 2026 YTD | $28.5 | $47.0 | +65% |
ALKS has finished higher in five of the last six years. It's up 65% so far in 2026.